Know Cancer

forgot password

A Randomized, Placebo-Controlled Phase 2b Study of Tamibarotene Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin as First Line Treatment for Subjects With Advanced Non-Small Cell Lung Cancer

Phase 2
18 Years
Not Enrolling
Stage IIIB Non-small Cell Lung Cancer With Pleural Effusion, Stage IV Non-small Cell Lung Cancer

Thank you

Trial Information

A Randomized, Placebo-Controlled Phase 2b Study of Tamibarotene Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin as First Line Treatment for Subjects With Advanced Non-Small Cell Lung Cancer

Inclusion Criteria:

- Subjects must be at least 18 years of age

- Subjects must have pathological findings consistent with primary non-small cell lung
cancer of any histology.

- Subjects must have either stage IIIB with pleural effusion or IV NSCLC with
radiographically measurable disease (RECIST 1.1 criteria). Women non-smokers with
stage IV NSCLC should be screened for EGFR mutation and if positive be excluded from
the study and placed on an EGFR kinase inhibitor.

- Subjects must have an ECOG Performance Status ≤2.

- If corticosteroids are required for controlling cerebral edema, subjects must be on a
stable dose for at least 1 week.

- Subjects must have recovered from any toxicity of prior therapies.

- Subjects must be at least 4 weeks removed from surgery or radiation therapy.

- Subjects must have a life expectancy of at least 12 weeks.

- Subjects must have adequate bone marrow function (defined as an absolute neutrophil
count of ≥1500 cells/mm3 and platelet count ≥100,000 cells/mm3), liver function with
total bilirubin ≤2.0 mg/dL, and serum creatinine ≤1.5 x institutional ULN.

- Subjects must be able to understand and be willing to sign a written informed consent

- Tamibarotene, as with all retinoids, is teratogenic. Therefore, female subjects of
childbearing potential must agree to use 2 effective methods of contraception
(hormonal, barrier method of birth control, or abstinence) and sexually-active male
subjects must agree to use an effective method of contraception (hormonal or barrier
method of birth control or abstinence) while participating in this study and for six
months afterwards. Women of childbearing potential must have a negative pregnancy
test ≤1 week prior to registration.

- Subjects must be able to swallow tablets.

- If available, tumor specimens must be submitted for immunohistochemistry analyses
with their pathology reports.

Exclusion Criteria:

- Subjects who have received or are currently receiving chemotherapy or antibody
therapy, or are enrolled in another treatment clinical trial.

- Subjects with a coagulopathy or bleeding disorder.

- Clinically evident congestive heart failure >class II of the New York Heart
Association (NYHA) guidelines.

- Serious, clinically significant cardiac arrhythmias, defined as the existence of an
absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V.

- History or signs of active coronary artery disease with or without angina pectoris
(i.e. myocardial infarction with 6 months prior to enrollment, uncontrolled angina,
electrocardiographic evidence of acute ischemia).

- Subjects who have a serious medical or psychiatric illness that could, in the
investigator's opinion, potentially interfere with the completion of treatment
according to this protocol or may not be able to comply with the safety monitoring
requirements of the study.

- HIV-positive subjects; however, subjects will not be routinely screened for HIV.

- Subjects who are allergic to any of the intended chemotherapies.

- Female subjects who are pregnant or breast-feeding.

- Active, clinically significant serious infection requiring treatment with
antibiotics, antivirals, or antifungals.

- Subjects with peripheral neuropathy ≥grade 2

- Prior systemic treatment for locally advanced or metastatic disease (exception
below): Prior adjuvant chemotherapy for Stage I-III or combined modality
chemotherapy-radiation for locally advanced disease allowed if completed >12 months
prior to randomization.

- Subjects with brain metastases are only eligible if treated and neurologically stable
with no ongoing requirement for corticosteroids, e.g., dexamethasone, for at least 2

- Subjects with hypertriglyceridemia (>1000 mg/dL).

- Subjects with elevated liver function tests if AST is ≥2.5x the institutional or
central laboratory's upper limit of normal for subjects without liver metastases, or
>5x the institutional or central laboratory's upper limit of normal for subjects with
liver metastases.

- Subjects with HbA1c ≥8.0.

- Subjects taking vitamin A either as a supplement or as part of a multivitamin unless
there has been at least a 2 week washout.

- Subjects using concomitant medications that are known inducers or inhibitors of
CYP3A4 up to 14 days before Cycle 1 Day 1 (pimozide, diltiazem, erythromycin,
clarithromycin, and quinidine, and amiodarone) should be excluded from the study.

- Subjects whose tumors cannot be adequately measured per RECIST 1.1.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:

Progression-free survival

Outcome Description:

Progression-free survival (PFS) is defined as the time from enrollment (i.e., assignment of subject ID number) to first documentation of objective tumor progression or to death due to any cause in the absence of previous documentation of objective tumor progression.

Outcome Time Frame:

Within 18 months of study start.

Safety Issue:


Principal Investigator

Oscar Arrieta, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Instituto Nacional de Cancerologia, Columbia


United States: Food and Drug Administration

Study ID:




Start Date:

April 2011

Completion Date:

June 2013

Related Keywords:

  • Stage IIIB Non-small Cell Lung Cancer With Pleural Effusion
  • Stage IV Non-Small Cell Lung Cancer
  • non-small cell lung cancer
  • tamibarotene
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Pleural Effusion



Hackensack University Medical Center Hackensack, New Jersey  07601
Desert Hematology Oncology Medical Group, Inc. Rancho Mirage, California  92270
Kansas City Cancer Center Kansas City, Kansas  66112